

1 **Safety and immunogenicity following co-administration of Yellow fever**
2 **vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines:**
3 **Results from an open label, non-randomized clinical trial**

4
5 John Tyler Sandberg¹, Marie Löfling¹, Renata Varnaitė¹, Johanna Emgård¹, Nabil Al-Tawil²,
6 Lars Lindquist³, Sara Gredmark-Russ^{1,3}, Jonas Klingström¹, Karin Loré⁴, Kim Blom^{1*}, Hans-
7 Gustaf Ljunggren^{1*#}

- 8
9 1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
10 Stockholm, Sweden
11
12 2. Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden
13
14 3. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
15
16 4. Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet
17 and Karolinska University Hospital, Stockholm, Sweden
18

19 #Corresponding author: hans-gustaf.ljunggren@ki.se

20

21 *Shared senior author (alphabetic order)

22

23 Short title: Safety and immunogenicity following co-administration of flavivirus vaccines

24

25 **Funding**

26 This work was supported by the Swedish Research Council (2015-02499, 2020-01365; HGL),
27 the Swedish Foundation for Strategic Research (SB12-0003; HGL), Region Stockholm (CIMED
28 2020-2022; HGL and KB), Karolinska Institutet (HGL), and a KID PhD student funding grant
29 from Karolinska Institutet (for JTS; HGL).

30

31 **URLs to sponsors' websites**

32 [https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-virus-](https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-virus-infections-and-cancer)
33 [infections-and-cancer](https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-virus-infections-and-cancer)

34

35 **Competing interest**

36 The authors declare no competing interest

37

38

39

40 **Abbreviations**

41	AE	adverse event
42	Ab	antibody
43	ED50	50% effective dose
44	ELISA	enzyme linked immunosorbent assay
45	JEV	japanese encephalitis virus
46	nAb	neutralizing antibody
47	PCR	polymerase chain reaction
48	RFFIT	rapid fluorescent focus inhibition test
49	SAE	serious adverse event
50	TBEV	tick-borne encephalitis virus
51	YFV	yellow fever virus

52 **Author summary**

53

54 **Why was this study done?**

- 55 • Flavivirus infections pose a significant global health burden, underscoring the need for
56 the development of safe and efficient vaccination strategies
- 57 • Co-administration of different flavivirus vaccines saves time and visits to health care
58 units and vaccine clinics. It serves to provide protection against multiple pathogens in a
59 shorter time-span, both for individuals living in or travelling to endemic areas
- 60 • Safety and immunogenicity-related responses have not been appropriately evaluated upon
61 co-administration of many vaccines including currently used flavivirus vaccines, such as
62 Yellow fever virus (YFV), Tick-borne encephalitis virus (TBEV), and Japanese
63 encephalitis virus (JE) virus vaccines
- 64 • Because of this, we performed an open label, non-randomized clinical trial studying the
65 safety and immunogenicity following co-administration of YFV vaccine with TBEV and
66 JEV vaccines

67

68 **What did the researchers find?**

- 69 • Adverse events, neutralizing antibodies (nAbs) and other related immunological
70 parameters were not adversely affected by concomitant delivery of the vaccines
- 71 • Concomitant vaccination in the same versus different upper arms of study participants did
72 not significantly affect safety or immunogenicity outcomes

73

74 **What do these findings mean?**

- 75 • Co-administration of YFV vaccine and TBEV or JEV vaccines is feasible without
76 increased risk of adverse events or reduced development of nAbs against the respective
77 viruses. Furthermore, the vaccines can safely be delivered in the same upper arm without
78 negative outcome

79 **Abstract**

80 **Background**

81 Flavivirus infections pose a significant global health burden underscoring the need for the
82 development of safe and efficient vaccination strategies. Available flavivirus vaccines are from
83 time to time concomitantly delivered to individuals in need. Co-administration of different
84 vaccines saves time and visits to health care units and vaccine clinics. It serves to provide
85 protection against multiple pathogens in a shorter time-span, both for individuals living in, or
86 travelling to, endemic areas. However, safety and immunogenicity-related responses have not
87 been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we
88 performed an open label, non-randomized clinical trial studying the safety and immunogenicity
89 following concomitant delivery of the Yellow fever virus (YFV) vaccine with Tick-borne
90 encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines.

91

92 **Methods and findings**

93 Following screening, healthy study subjects were enrolled into different cohorts receiving either
94 TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the
95 TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper
96 arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the
97 study period and blood samples were taken before and at multiple time-points following
98 vaccination to evaluate immunological responses to the vaccines. Adverse events were
99 predominantly mild in the study groups. Four serious adverse events (SAE) were reported
100 throughout the trial, none of them deemed related to vaccination. The development of
101 neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant

102 vaccination strategy. Concomitant vaccination in the same or different upper arms did not
103 significantly affect safety or immunogenicity-related outcomes. Exploratory studies on
104 immunological effects were additionally performed and included studies of lymphocyte
105 activation, correlates associated with germinal center activation, and plasmablast expansion.

106

107 **Conclusions**

108 Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine
109 without an increased risk of adverse events and without reduced development of nAbs to the
110 respective viruses. The vaccines can be delivered in the same upper arm without negative
111 outcome.

112

113 **Trial registration**

114 Eudra CT 2017-002137-32

115

116 **Introduction**

117 Yellow fever virus (YFV), Tick-borne encephalitis virus (TBEV), and Japanese encephalitis
118 virus (JEV) all belong to the *Flavivirus* genus of the *Flaviviridae* family of viruses. These
119 viruses pose major global health challenges, both for inhabitants in affected areas (around 1/3 of
120 the world's population) as well as for travelers to these areas [1–5]. Infection with these viruses
121 is associated with significant morbidities, hospitalization costs, sick leave-associated costs, and
122 loss of productivity as well as over 100,000 of fatal outcomes per year [2,4,6–9]. No specific
123 treatment or antiviral drugs for these diseases exists, though development of antiviral drug
124 candidates has been initiated [10–14]. There are, however, approved vaccines against these
125 flaviviruses [15–17]. These vaccines are frequently used to prevent disease among inhabitants
126 living in endemic areas and for travelers visiting these areas.

127 The vaccine regimen and outcome of vaccinations against YFV, TBEV, and JEV
128 infections differ significantly. After a single dose, the live attenuated YFV vaccine provides at
129 least 10 years, and possibly life-long, immunity [18–20]. In contrast, the current inactivated
130 TBEV and JEV vaccines licensed in Europe require multiple doses for primary immunization
131 and regular booster doses to maintain immunity [15,16,20,21].

132 Safe and efficient vaccine administration strategies are of significant importance [22].
133 Rigorous clinical trials have assessed the safety and immunogenicity of most currently approved
134 vaccines. However, data are limited with respect to interactions of many vaccines, including the
135 YFV vaccine, with other vaccines including all currently available flavivirus vaccines [23–32].
136 Published studies are limited to a few reports on concomitant vaccination of the YFV vaccine
137 with other vaccines including smallpox, Bacillus Calmett-Guérin (BCG), hepatitis B or cholera
138 vaccines [33–35].

139 Endemic flaviviruses overlap in some parts of the world, affecting local inhabitants as
140 well as travelers with needs for protection. Simultaneous vaccination with different vaccines
141 saves time and visits to health care units and vaccine clinics. It provides protection against
142 multiple pathogens in a shorter time-span when an individual may be vulnerable to infection. As
143 mentioned, there is also often a need for individuals to rapidly protect themselves from
144 flaviviruses prior to travelling to endemic areas. This has been further emphasized more recently
145 given that present flavivirus endemic areas are currently increasing, likely due to changes in
146 climate change and other factors [1,36–38]. Together, this has called for more systematic
147 evaluations of the effects of concomitant delivery of flavivirus vaccines, particularly with respect
148 to safety and immunogenicity.

149 To this end, we carried out an open label, non-randomized clinical trial assessing the
150 safety and immunogenicity of concomitant vaccination with different commonly used flavivirus
151 vaccines. The clinical trial included healthy adult volunteers who were concomitantly vaccinated
152 with TBEV and YFV vaccines, JEV and YFV vaccines, or with only one of the three respective
153 vaccines. Half of the concomitantly vaccinated study participants received both vaccines in the
154 same upper arm while the other half received the vaccines in different upper arms. Blood
155 samples were taken before and at multiple time-points following vaccinations. Safety and
156 immunological responses including nAbs were evaluated. Collectively, the study provides safety
157 and immunogenicity outcomes following concomitant vaccination with different types of
158 flavivirus vaccines.

159 **Methods**

160 **Ethical and regulatory approval**

161 The study was approved by the Stockholm Local Regional Ethical Committee (2017/1433-31/1)
162 and the Swedish Medical Products Agency (5.1-2017-52376). It is registered in the European
163 database (Eudra CT 2017-002137-32). All study volunteers signed informed consent documents
164 in line with the ethical approval and clinical trial protocol.

165

166 **Study design and participants**

167 An open label, non-randomized academic (non-Pharma sponsored) clinical trial was conducted
168 in order to assess safety and immunological responses of concomitant vaccination with three
169 currently licensed flavivirus vaccines. The trial was conducted at the Karolinska University
170 Hospital, Stockholm, Sweden. An independent data monitoring process was setup by the
171 Karolinska Trial Alliance (KTA) support organization (KTA Support) in order to review safety
172 data and the progress of the study according to the clinical trial protocol. The monitoring process
173 also included review of the trial's conductance in accordance with principles of good clinical
174 practice (ICH-GCP)[39]. Volunteer recruitment, medical examination, vaccination, and
175 peripheral blood sampling were handled by the KTA Phase I unit at the Karolinska University
176 Hospital. Recording of informed consent, adherence to set inclusion and exclusions criteria
177 including previous vaccinations, age, gender, and a standardized medical examination was
178 performed (including temperature, pulse, blood pressure, and pregnancy test) prior to inclusion
179 in the study. Inclusion criteria allowed volunteers between 18 to 55 years of age who wanted

180 protection to YFV, TBEV, and/or JEV, and who were willing to provide written consent to enter
181 the study. Exclusion criteria included, but were not limited to, previous known infection with or
182 vaccination against YFV, TBEV, and JEV, allergy to eggs, poultry or fructose,
183 immunocompromising diseases, autoimmune diseases, medication for cancer or
184 immunosuppression, HIV or HCV infection, fever within one week of scheduled vaccination,
185 pregnancy, hemophilia, and/or involvement in other medical studies. All study volunteers were
186 properly insured with respect to vaccination and blood sampling risks. Study participants were
187 entitled to leave the study at any time without reason. Further details with respect to exclusion
188 criteria and specific criteria for termination of the study are outlined in the clinical trial protocol.
189

190 **Vaccines**

191 The following vaccines were used in the trial: Stamaril[®] (Sanofi), live, attenuated YFV 17D
192 strain produced in pathogen-free chick embryo cells, 0.5 ml, not less than 1,000 IU. The vaccine
193 was provided in freeze dried powder form and reconstituted with provided saline solution and
194 was administered subcutaneously. IXIARO[®] (Valneva), inactivated, alum-adjuvanted, Vero cell-
195 derived vaccine based on JEV strain SA₁₄₋₁₄₋₂, 0.5 ml. The vaccine was provided in the form of
196 pre-filled syringe attached without needle containing an 0.5 mL dose and was administered
197 intramuscularly according to the manufacturer's label. FSME IMMUN[®] (Pfizer), inactivated,
198 alum-adjuvanted, chick embryo cell derived vaccine based on the Neudörfl strain, 0.5 ml. The
199 vaccine was provided as a pre-filled syringe attached without needle containing a 0.5 mL dose
200 and was administered intramuscularly according to the manufacturer's label. All vaccines were
201 obtained from Apoteket AB, Karolinska University Hospital, Solna, Sweden and kept at the
202 Phase-1 unit, KTA, Karolinska University Hospital, at its Huddinge site.

203

204 **Study design and cohorts**

205 The study was initially designed to include a total of 140 healthy volunteers. Forty study
206 participants were to receive both TBEV and YFV vaccines (cohort A). Twenty of these
207 participants were to receive the vaccines in different upper arms (sub-cohort A1) and the other
208 20 in the same upper arm (sub-cohort A2). The next 40 study participants were to receive both
209 JEV and YFV vaccines (cohort B). Similarly, 20 of these participants were to receive the
210 vaccines in different upper arms (sub-cohort B1) and the other 20 in the same upper arm (sub-
211 cohort B2). The remaining three cohorts of 20 study participants per cohort, were aimed to serve
212 as study controls and were to receive either, the TBEV vaccine (cohort C), JEV vaccine (cohort
213 D), or YFV vaccine (cohort E).

214 Upon initiation of the clinical trial, a total of 161 healthy volunteers were screened for
215 enrollment (**Fig 1A**). 145 study participants were found eligible for entering the study and
216 assigned to it. Of these, 43 participants were assigned to cohort A (A1, 23 participants; A2, 20
217 participants), 42 participants to cohort B (B1, 21 participants; B2, 21 participants), and 20
218 participants each to cohorts C, D, and E. Cohort A1 had in total three study participant dropouts
219 and cohorts B1, B2, and C had one study participant dropout each, following enrollment to the
220 study. Hence, 139 study subjects in total completed the trial. A total of 13 missed visits out of
221 1,150 total planned visits occurred during the course of the trial.

222

223 **Procedures**

224 Vaccinations were given in accordance with the clinical trial protocol and good clinical practice
225 (GCP), with intervals for primary vaccinations as recommended in FASS (Pharmaceutical
226 Specialties in Sweden): FSME IMMUN, three doses 0-, 1- and 5-month intervals; IXIARO, two
227 doses, 0- and 1-month interval; Stamaril, one dose. For cohorts A1, A2, B1, B2, C, and D, blood
228 and serum were sampled before each vaccination, and then at day 7 (+/- 1 day) and at day 14.
229 Blood and serum were also sampled 30 days after the last vaccination (+14 days). For cohort E,
230 blood and serum were sampled before the vaccination, and then at day 7 (+/- 1 day), at day 14, at
231 day 30 (+/-2 days), day 37 (+/- 1 day), day 44 (+5 days) and day 60 (+14 days). This schedule
232 led to the following approximate time allocations in terms of days for blood and serum
233 samplings: cohorts A and C, days 0 (first vaccination), 7, 14, 30 (second vaccination), 37, 44,
234 180 (third vaccination), 187, 194, and 210; cohorts B and D, days 0 (first vaccination), 7, 14, 30
235 (second vaccination), 37, 44, and 60; cohort E, days 0 (vaccination), 7, 14, 30, 37, 44, and 60
236 (**Fig 1B**). At each sampling time-point, 40-45 ml of venous blood from study participants was
237 collected in vacuum serum and EDTA tubes (BD). PBMCs were isolated using gradient
238 centrifugation and used for immediate analyses as well as also being cryopreserved for
239 subsequent studies. Serum tubes were allowed to stand upright for 2 hours at room temperature.
240 Serum was subsequently isolated by centrifugation at 2,000 X g for 10 minutes and stored at -
241 80°C for later analysis.

242

243 **Safety assessment**

244 Results from physical examination, including vital signs and body temperature, pulse, and blood
245 pressure was recorded at each time-point for vaccination. Adverse events (AEs) following
246 vaccinations were recorded from each study participant at each visit and classified as mild,
247 moderate, or severe. Severe adverse events were, when so deemed, classified as serious adverse
248 events (SAEs). AEs and SAEs recorded for all study participants were deemed unlikely,
249 possible, or probably related to the vaccinations.

250

251 **Determination of YFV RNA levels in serum**

252 YFV-specific real-time PCR was used to determine the viral RNA in serum of study participants.
253 RNA was isolated from 150 μ L of serum using a NucleoSpin RNA Virus Kit (Machery-Nagel).
254 One step real-time PCR was performed using TaqMan Fast Virus 1-Step Master Mix (Applied
255 Biosystems), a FAM-TAMRA-labeled probe and primers (Fisher Biotechnology) according to
256 the manufacturer's instructions. The primers and probe were all specific for the highly conserved
257 NS5 gene of YFV [40] and were used at a final concentration of 800 nM and 125 nM for the
258 primers and probe, respectively. Amplifications were performed in 25 μ L reactions using a
259 QuantStudio 5 real-time PCR machine (Applied Biosystems) under the following thermal
260 cycling conditions: 5 min at 50°C, 20 s at 95°C, 45 cycles of 15 s at 95°C, followed by 1 min at
261 60°C. RNA from the YFV 17D was calibrated in relation to a standard curve commercially
262 available in the Techne qPCR test for YFV (Techne) and used for quantification. The limit of
263 detection was 20 copies per 1 mL.

264

265 **Clinical chemistry**

266 C-reactive protein (CRP), albumin (ALB), creatinine, bilirubin, aspartate transaminase (AST),
267 alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyltransferase
268 (GGT) were analyzed at the Karolinska University Hospital accredited clinical chemistry
269 laboratory at the first three time-points (days 0, 7, and 14).

270

271 **Absolute cell counts**

272 Absolute numbers of cells expressing CD45, CD3, CD4, and CD8 in peripheral blood were
273 measured using BD Trucount™ tubes (BD Biosciences) according to the manufacturer's
274 instructions. Briefly, 50 µL of anticoagulated blood was added to Trucount™ tubes within three
275 hours after extraction and thereafter fluorescently stained for CD45, CD3, CD4, and CD8 for 15
276 minutes at RT in the dark. Samples were then fixed with 1X BD FACS lysing solution before
277 acquiring data on a BD Accuri flow cytometer (BD Biosciences).

278

279 **Multiplex measurement of cytokine secretion**

280 GM-CSF, IFN- γ , IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN- α 2, MIP-1 β , IL-12, IL-15 and IL-18
281 were measured in serum, diluted 1:4, from the first four time-points (days 0, 7, 14, and 30) from
282 each study participant using a pre-designed 8-plex assay with a custom-designed 5 single-plex
283 assay Bio-Plex Pro Human Cytokine Assay (Bio-Rad), according to the manufacturer's
284 instructions.

285

286 **Antibody analyses**

287 Assessment of virus-specific IgG levels and neutralizing antibody titers (nAbs) against TBEV,
288 JEV and/or YFV was performed on day 0, day 30, and at the final time-point of the clinical trial
289 (day 210 for cohort A and cohort C, day 60 for B, D, and E). TBEV-specific IgG antibodies were
290 assessed using an anti-TBE virus ELISA “Vienna” (IgG) kit (Euroimmun) and JEV-specific IgG
291 antibodies were assessed using an anti-JEV ELISA (IgG) kit (Euroimmun) according to the
292 manufacturer’s instructions. Both assays included complete virus lysates as coating antigen.
293 Antibody levels equal to, or greater than, 120 were considered seropositive for TBEV-specific
294 IgG and levels equal to, or greater than, 20 were considered seropositive of JEV-specific IgG,
295 both as determined by the ELISA kit manufacturer. TBEV-specific IgG levels $\geq 1,000$ Vienna
296 units were recorded as 1,000 Vienna units and likewise, JEV-specific IgG levels ≥ 200 RU/ml
297 were recorded as 200 RU/ml.

298 Virus neutralization was measured by rapid fluorescent focus inhibition test (RFFIT) as
299 previously described with modifications for TBEV, JEV and YFV [41]. Briefly, serum from days
300 0, 30 and the final time-point (day 210 for cohort A and cohort C, day 60 for B, D, and E) were
301 heat-inactivated and tested in serial dilutions with fifty 50% focus-forming doses of either TBEV
302 (93-783 strain), JEV (*Nakayama* strain) or YFV (*Asibi* strain) in flat-bottom 96-well plates.
303 Following a 90-minute incubation of serum and virus, 50,000 trypsinized BHK-21 cells were
304 added to each well and the plates were incubated for 24 hours. Following incubation, cells and
305 virus were discarded and then fixed in 80% acetone for 1 hour at -20° C. After fixation, virus
306 infected cells were detected by staining with optimized dilutions of mouse anti-TBEV (clone
307 1004134, Bio-Techne), mouse anti-JEV (clone 6B4A-10, Merck) or mouse anti-YFV (clone
308 2D12-A, Merck) followed by detection with Alexa Fluor 488 AffiniPure goat anti-mouse IgG

309 (H+L) (Jackson ImmunoResearch). Virus infected cells were detected using fluorescence
310 microscopy and an IRIS FluoroSpot reader (Mabtech). In each well, 20 fields were examined for
311 fluorescent foci (infected cells) and fields with one or more foci were recorded. Titers are
312 defined as 50% effective dose (ED50) and reciprocal titers of $ED50 \geq 5$ were deemed positive.
313 Titers less than 5 showed no neutralizing capacity or less than 50% reduction.

314

315 **Flow cytometry**

316 Freshly isolated PBMCs were used for phenotypical analysis using the following antibodies:
317 Live/Dead cell marker Near IR (Life Sciences), anti-CD19 (clone SIJ25C1) BUV 395, anti-CD4
318 (clone SK3) BUV 737, anti-CD16 (clone 3GB) Pacific Blue, anti-CD14 (clone M ϕ P9) AmCyan,
319 anti-Ki67 (clone B56) AF700 (BD Biosciences), anti-CD20 (clone 2H7) FITC, anti-CD123
320 (clone 6H6) AmCyan, anti-CD27 (clone O323) BV650, anti-CD38 (clone HIT2) BV785, anti-
321 IgD (clone IA6-2) PE-Cy7, anti-IgG (clone HP6017) PE (BioLegend), anti-CD56 (clone N901)
322 ECD, anti-CD3 (clone UCHt1) PE-Cy5 (Beckman Coulter), anti-CD8 (clone 3B5) Qdot 605
323 (Invitrogen) and anti-IgA (clone IS11-8E10) APC (Miltenyi Biotech). Cells were incubated with
324 50 μ L of surface staining antibody mix diluted in PBS for 30 minutes at 4°C in the dark.
325 Following incubation, the cells were washed twice in FACS buffer (2% FCS and 2 mM EDTA in
326 PBS) and then fixed and permeabilized using Foxp3/Transcription Factor Staining kit
327 (eBioscience) for 30 minutes at 4°C. Cells were then washed twice in permeabilization buffer
328 (eBioscience) followed by intracellular staining. Antibodies against Ki67 and IgG in
329 permeabilization buffer were added to the cells and incubated in the dark for 30 minutes at 4°C.
330 Cells were finally washed with FACS buffer and data acquired on a BD LSR Fortessa (BD
331 Bioscience). Analysis of acquired data was done with FlowJo software version 10 (FlowJo Inc).

332

333 **CXCL13 ELISA**

334 Undiluted serum was thawed at room temperature and analyzed using a Quantikine Human
335 CXCL13/BLC/BCA-1 ELISA (R&D Systems) according to the manufacturer's instructions.
336 Limit of detection of the assay ranged between 7.8 and 500 pg/mL.

337

338 **Statistics**

339 Statistical analyses were performed using GraphPad Prism (GraphPad Software). Data sets were
340 analyzed using non-parametric Wilcoxon matched-pairs signed rank test, Kruskal-Wallis, or
341 Friedman tests. Dunn's multiple comparisons test was used to correct for multiple comparisons
342 where applicable. Handling of missing values due to missed visits (13 out of 1,150 visits) were
343 determined before analysis according to the study protocol. In line with this, missing values were
344 imputed in Figs using median values from the specific time-point in each cohort. All p -values
345 <0.05 were considered to be statistically significant ($*p < 0.05$; $**p < 0.01$; and $***p < 0.001$).

346

347 **Results**

348 **Study participants and vaccination schedule**

349 140 study subjects were planned for the present clinical trial. Over the course of 17 months, 161
350 volunteers were screened, 145 of whom were found to be eligible for the clinical trial and
351 enrolled into one of the seven cohorts (A1, A2, B1, B2, C, D, and E). All but six study
352 participants completed the trial, leaving the clinical trial with a final 139 study participants (**Fig**
353 **1A**). These 139 study participants all completed the full duration of the study and were included
354 in subsequent safety and immunogenicity assessments. Cohorts A1 and A2 (n=40) received the
355 TBEV and YFV vaccine at day 0, and subsequent TBEV vaccine doses 1 month after the first
356 dose, and at 5 months after the second dose. Cohort A1 (n=20) received TBEV and YFV
357 vaccines in different upper arms and cohort A2 (n=20) in the same upper arm. Cohorts B1 and
358 B2 (n=40) received the JEV and YFV vaccine at day 0, and subsequent JEV vaccine
359 dose at 1 month after the first dose. Cohort B1 (n=20) received JEV and YFV vaccines in
360 different upper arms and cohort B2 (n=20) in the same upper arm. Cohorts C (n=19), D (n=20)
361 and E (n=20) received TBEV, JEV, or YFV vaccinations, respectively, following the same dose
362 schedule as described in cohorts A and B (**Fig 1B**). The study participants were age and sex-
363 matched across the cohorts (**Table 1**).

Table 1 | Cohort characteristics

	A1 (n=20)	A2 (n=20)	B1 (n=20)	B2 (n=20)	C (n=19)	D (n=20)	E (n=20)	All cohorts (n=139)
Age (years)								
Average (SD)	31.3 (9)	28.9 (7.1)	28.3 (10.2)	27.8 (4.6)	24.4 (5.9)	26 (6.3)	29.7 (9.5)	28.1 (7.9)
Median (IQR)	29 (10.5)	25.5 (7.8)	25 (6)	27.5 (7)	23 (4)	25 (2.5)	28.5 (11.8)	26 (7)
Min, Max	18. 53	22. 46	21. 53	22. 38	20. 46	18. 47	18. 54	18. 54
Gender (%)								
Male	7 (35)	6 (30)	9 (45)	10 (50)	6 (31.6)	7 (35)	8 (40)	53 (38.1)
Female	13 (65)	14 (70)	11 (55)	10 (50)	13 (68.4)	13 (65)	12 (60)	86 (61.9)

364

365 **Adverse events**

366 69.8% of the 139 included study participants reported one or more AEs during the course of the
 367 clinical trial (**Table 2**). 77.4% of all AEs across all cohorts were mild, 20.8% were moderate, and
 368 1.8% were severe. 65.2% of all AEs across all cohorts were deemed unlikely related to
 369 vaccination, while 11.8% were deemed possibly related to vaccination and 23.1% were deemed
 370 probably related to vaccination (**Table 2**).

371

372

373

374 The most frequent AEs were common cold-like symptoms followed by redness/tenderness at the
 375 injection site, headache, fever, and influenza-like symptoms. The latter four symptoms represent
 376 classical reactogenicity related responses.

377 Cohorts A1, A2 and C, all of which received TBEV vaccinations, had a greater number of total
 378 registered AEs compared to the other cohorts, ascribed to multiple (n=3) TBEV vaccinations.

379 Cohorts B1, B2, and D, all of which received JEV vaccinations, had greater number of total

380 registered AEs compared to the E cohort, concordantly ascribed to multiple (n=2) JEV
 381 vaccinations. Four AEs were deemed severe, all of which were determined SAEs. These SAEs
 382 included one case with hip dysplasia in a newborn child of a study participant, one case with
 383 pneumonitis, one case with depression, and one case with a fall, all four of which were
 384 determined to be unrelated to vaccination. A full list of the cohorts' AEs is shown in **STables 1**
 385 **and 2**.

Table 2 | Summary of registered adverse events

	A1 (n=20)	A2 (n=20)	B1 (n=20)	B2 (n=20)	C (n=19)	D (n=20)	E (n=20)	Total (n=139)
Total AE	40	51	25	19	36	31	19	221
Donors with at least one AE	18	15	12	10	15	16	11	97
Severity:								
Mild	35	35	21	12	26	26	16	171
Moderate	4	15	4	7	9	5	2	46
Severe	1	1	0	0	1	0	1	4
Related to vaccination								
Unlikely	25	36	18	8	21	20	16	144
Possible	5	3	2	8	5	1	2	26
Probable	10	12	5	3	10	10	1	51

386

387 **Viral RNA levels, clinical chemistry, and immunology**

388 The YFV vaccine causes a mild infection, often with detectable virus in circulation. As a safety-
 389 related assessment, we measured serum YFV NS5-RNA levels in all cohorts vaccinated with the
 390 YFV vaccine in order to assess if concomitant vaccination had any effects on YFV viral
 391 replication. Across all study cohorts, most study participants receiving the YFV vaccine had
 392 detectable levels of YFV NS5-RNA seven days after vaccination (**Fig 2A**). In all but four study
 393 participants, no YFV NS5-RNA was detectable at 14 days following vaccination. Overall, no

394 significant differences were observed between the study cohorts with the exception of cohort B2
395 which was found to have somewhat higher median levels of YFV NS5-RNA copies in serum
396 (**Fig 2B**). Based on these findings, we conclude that concomitant vaccination did not generally
397 affect YFV replication in the study participants receiving concomitant vaccination.

398 As YFV infection can lead to liver and kidney damage, we assessed common
399 inflammation as well as kidney- and liver-related clinical chemistry analytes to evaluate the
400 effects of concomitant vaccination. No significant changes were observed over time in the
401 cohorts with most clinical chemistry values lying within the normal range for healthy individuals
402 (**Fig 2C**). These findings suggest that TBEV or JEV vaccination together with the YFV vaccine
403 have no major systemic effects on kidney or liver organ function.

404 Further laboratory assessment included basic cellular immunological measurements
405 following concomitant vaccination. This included standardized clinical diagnostic TruCount
406 assays, in which absolute numbers of CD45⁺, CD4⁺, and CD8⁺ cells were measured (**Fig 2D**).
407 Increases in CD45⁺ and CD4⁺ cell numbers were, as expected, observed at day 14 after
408 vaccination in all cohorts. Similarly, CD8⁺ cells increased in absolute number 14 days following
409 vaccination, however, only in cohorts receiving the YFV vaccine. There were no general
410 differences in absolute cell counts at day 14 between the study cohorts when assessing overall
411 patterns compared to days 0, 7 and 30, respectively.

412 As a final laboratory measurement assessing concomitant vaccination, multiple soluble
413 cytokines and chemokines were measured in serum before and at the three first time points
414 following vaccination in all cohorts. Of these, IL-18, IL-8, TNF and MIP-1 β were at detectable
415 levels among most study participants while GM-CSF, IFN- γ , IL-2, IL-4, IL-6, IL-10, IFN- α 2,
416 IL-12, and IL-15 were below detection levels in the majority of study participants (**S1 Fig**).

417 Notable increases in TNF and IL-18 levels were observed in all cohorts receiving the YFV
418 vaccine (cohorts A1, A2, B1, B2, and E) (**Fig 2E**). There were no statistically significant
419 differences in TNF or IL-18 levels between these cohorts at any of the measured time-points.

420 Taken together, no marked clinical safety-related effects following concomitant
421 vaccination of the TBEV or JEV vaccines with the YFV vaccine were observed. Nor were there
422 any statistical differences observed when vaccines were administered in the same or different
423 upper arms of study participants.

424

425 **Virus specific IgG levels**

426 As part of the primary endpoint, TBEV and JEV specific IgG levels were measured before
427 vaccination and at days 30 (30 days after dose 1) and 210 (30 days after dose 3) for the TBEV
428 vaccine cohorts, and at days 30 (30 days after dose 1) and 60 (30 days after dose 2) for the JEV
429 vaccine cohorts.

430 Study participants from cohorts A1, A2, and C all developed IgG antibodies against
431 TBEV by the end of the trial (**Fig 3A**). A total of six study participants from these three cohorts
432 had pre-existing antibodies at day 0 by using the detection threshold (≥ 120 Vienna units) for
433 positive response as defined by the manufacturer. For all cohorts, a gradual increase of virus
434 specific IgG levels was observed as assessed at day 30 and day 210 (**Fig 3A**). All responses were
435 above the positive threshold at the final time-point (**Fig 3B**). Cohorts A1, A2, and C did not
436 differ significantly from each other (**Fig 3B**). The majority of study participants from cohorts B1,
437 B2, and D developed IgG antibodies against JEV by the end of the trial (**Fig 3C**). A total of 18
438 study participants from these three cohorts presented with pre-existing antibodies at day 0
439 according to the manufacturer's positive threshold (≥ 20 RU/mL). For all cohorts, a gradual

440 increase of virus specific IgG levels was observed as assessed at day 30 and day 60 (**Fig 3C**). At
441 the final time-point, no significant differences in antibody titers were observed between cohorts
442 B1, B2, and D (**Fig 3D**). Consequently, cohorts B1 and B2 did not differ significantly from each
443 other (**Fig 3D**).

444

445 **Virus neutralization**

446 Apart from the assessment of antigen-binding IgG responses, rapid fluorescence focus inhibition
447 tests (RFFIT) were performed to measure nAb titers against TBEV, JEV, and YFV to compare
448 the effect of concomitant vaccinations with respective single vaccination outcomes. All study
449 participants were screened at day 0 for nAbs against the three flaviviruses. Two study
450 participants had nAbs against TBEV at day 0 (one each from cohorts A1 and A2, respectively).
451 These were excluded from subsequent analyses. No study participants had preexisting nAbs
452 against JEV or YFV at day 0.

453 Few study participants developed TBEV nAbs at day 30, however, the majority
454 developed positive titers by day 210 (30 days after third dose) (A1: 85%, A2: 95%, and C: 79%)
455 (**Fig 3E**). There were no statistically significant differences in nAb titers between cohorts A1,
456 A2, and C (**Fig 3F**). Similarly, there were no statistically significant differences in nAb titers
457 when cohorts A1 and A2 were compared (**Fig 3F**). Similar to TBEV, few study participants
458 developed JEV nAbs at day 30, however, the majority developed positive titers by day 60 (30
459 days after third dose) (B1: 85%, B2: 55%, and D: 60%) (**Fig 3G**). There were no statistically
460 significant differences in nAb titers between cohorts B1, B2, and D (**Fig 3H**). There were no
461 statistically significant differences in nAb titers when cohorts B1 and B2 were compared (**Fig**
462 **3H**). All study participants from the cohorts receiving YFV vaccination developed nAbs by day

463 60 (**Fig 3I**). Additionally, there were no statistically significant differences in YFV nAb titers
464 between cohorts A1, A2, B1, B2, and E (**Fig 3J**).

465 No statistical differences were observed in terms of nAb titers were observed when
466 concomitant vaccinated study participants had received their respective vaccine in the same
467 upper arm (2.5 cm distance according to protocol) versus in different upper arms. A trend
468 towards higher titers (mean value) of nAb was noted in the groups where vaccines were given in
469 the same upper arm (cohorts A2 and B2) versus different upper arms (cohorts A1 and B1) (**Figs**
470 **3F and H**).

471 The design of the clinical trial also allowed us to divide the enrolled study subjects based
472 on gender. No statistically significant differences were observed between males and females in
473 terms of final nAb titers against TBEV, JEV, or YFV (**Fig S2**). Noteworthy, however, an
474 indication of an increase in females versus males in the TBEV-specific nAb titers were observed
475 when assessing all study participants receiving the TBEV vaccine (**Fig S2A, right panel**).

476 In summary, concomitant TBEV or JEV vaccination with YFV vaccine did not affect the
477 development of virus-specific nAbs towards TBEV or JEV. Likewise, YFV nAb titers did not
478 differ between the cohorts, whether the YFV vaccine was administered alone or together with the
479 TBEV or JEV vaccines (**Fig 3J**).

480

481 **Activation of B cells, T cells and NK cells**

482 In addition to the virus-specific binding IgG antibody responses and nAbs we, we expanded the
483 analyses in exploratory studies to investigate specific cellular responses following vaccination of
484 the different cohorts. Freshly isolated PBMCs from each time-point were used to assess the
485 effects of concomitant vaccinations on lymphocyte activation. Co-expression of CD38 and Ki67

486 in B cells, CD4⁺ T cells, CD8⁺ T cells, and NK cells (CD56^{dim} population of NK cells when not
487 else noted) was measured (**Fig 4A**). Cohorts A1, A2, B1, B2, and E (all vaccinated with the YFV
488 vaccine) exhibited increased frequencies of activated B cells, CD4⁺ T cells, CD8⁺ T cells, and
489 NK cells at day 14 following vaccination (**Fig 4B-E**). A trend towards earlier activation of NK
490 cells was observed in some study participants (**Fig 4E**), in line with previous reports [42,43]. In
491 general, vaccination with only YFV vaccine or vaccination with concomitant vaccination with
492 YFV vaccine and TBEV or JEV vaccine led to a stronger activation among these cellular subsets
493 compared to single vaccination with the TBEV or JEV virus vaccine (**Fig 4B-E**). No statistically
494 significant differences in lymphocyte activation were observed between cohorts A1 and A2, as
495 well as between B1 and B2 (**Fig 4B-E**), with the exception of a more marked CD4⁺ T cell
496 activation in group B2 versus group B1 (**Fig 4C**).

497

498 **Germinal center activation and plasmablast responses**

499 The observed activation of lymphocyte subsets indicates induction of innate and adaptive
500 immune responses, likely linked to the development of protective immunity (nAbs). We
501 therefore further explored parameters related to induction of humoral immunity such as germinal
502 center activity and plasmablast expansion following vaccination.

503 First, CXCL13 levels in serum were measured as a proxy to germinal center activity.
504 Elevated levels of serum CXCL13 were observed at days 7 and/or 14 following each vaccination
505 in all cohorts, with the most marked changes seen amongst vaccine cohorts receiving the YFV
506 vaccine (cohorts A1, A2, B1, B2, and E) (**Fig 5A**). Plasmablast expansion as a result of germinal
507 center formation was also analyzed. An increase in the number of plasmablasts was observed 14
508 days after vaccination in all cohorts receiving the YFV vaccine (cohorts A1, A2, B1, B2 and E)

509 (Fig 5B and C). Similar to B cell activation (Fig 4B), the concomitant vaccine cohorts (cohorts
510 A1, A2, B1, B2) had significantly higher frequencies of plasmablasts at day 14 than the single
511 TBEV and JEV vaccine cohorts (cohorts C and D). Additional deeper analyses were also
512 performed, including studies of plasmablast specific immunoglobulin expression over time (S3
513 Fig).

514 Together these findings indicated that concomitant TBEV or JEV vaccination with the
515 YFV vaccine leads to a marked germinal center activation and plasmablast expansion, likely
516 resulting to a significant extent from the YFV vaccine response.

517 **Discussion**

518 Here, we report the results of an open label, non-randomized, academic clinical trial assessing
519 the safety and immunogenicity upon concomitant vaccination with different commonly used
520 flavivirus vaccines. Healthy study participants were enrolled into cohorts receiving vaccines
521 against TBEV and YFV in different or the same upper arm, JEV and YFV in different or the
522 same upper arm, and in control cohorts receiving vaccines against TBEV, JEV, or YFV. Co-
523 administration of the TBEV or JEV vaccine with the YFV vaccine was well tolerated with
524 respect to reported AEs. Clinical virology, chemistry, and immunological assessments supported
525 these conclusions with no markedly unexpected responses observed. Serological responses
526 including virus-specific IgG levels and virus-specific nAb titers towards individual viruses were
527 not adversely affected by concomitant vaccination. Additional immunological studies added
528 deeper immunological insights into vaccine responses in concomitantly vaccinated study
529 participants and controls.

530 Of the AEs reported following vaccination, the majority were mild, dominated by
531 common cold symptoms followed by classical reactogenicity-related responses. The majority of
532 the reported AEs were deemed unrelated to vaccination. AEs related to vaccination (deemed
533 possible or probable) were in line with previous safety data of single vaccination studies and the
534 manufacturer's reported known side effects [15–17,44–46]. YFV RNA levels were generally
535 similar between the concomitant and YFV only vaccine cohort, supported by normal clinical
536 chemistry inflammation-, liver- and kidney-related parameters. Additionally, no marked
537 differences were observed in absolute CD45⁺, CD4⁺, or CD8⁺ cell counts as well as TNF or IL-
538 18 levels as well as other cytokine levels (data not shown), between concomitant and single
539 vaccination cohorts.

540 Earlier studies have shown the possible enhancement of cross-reactive flavivirus-specific
541 cellular and humoral immunity after flavivirus vaccinations [47–50]. These observations led us
542 to address if concomitant vaccination of flavivirus vaccines had any deviating effect on the
543 generation of virus-specific IgG and/or nAbs as well as on other immunological outcomes. All
544 TBEV vaccinated study participants were well above the defined positive threshold and were
545 found to have overall similar median IgG levels and nAb titers. In a similar manner, we assessed
546 JEV-specific IgG and nAbs in the JEV vaccine cohorts. All but four study participants developed
547 JEV-specific IgG levels above the positive threshold at the end of study with no differences
548 between the concomitant vaccine cohorts and the single JEV vaccine cohort. Not all study
549 participants receiving the JEV vaccine developed nAbs by the end of the study. Finally, all study
550 participants receiving the YFV vaccine developed nAbs by the end of the study and no
551 differences were found between the concomitant and YFV vaccine only cohorts. The findings
552 suggest that concomitant vaccination had no general negative effect on the development of
553 protective virus-specific serological responses.

554 In addition to assessing the effect of concomitant vaccination on serological outcomes,
555 we also assessed effects on lymphocyte activation and, in more detail, germinal center and
556 plasmablast responses. As expected, NK cell, T cell, and B cell activation was observed in the
557 cohorts receiving the live attenuated YFV vaccine (cohorts A1, A2, B1, B2 and E) in line with
558 previous research [42,43,51]. Cohorts C and D showed little to no increase in activation of these
559 cell subsets throughout the study, not unexpected from the inactivated TBEV and JEV vaccines,
560 respectively. Despite the lack of early cellular activation amongst cohorts C and D, this had no
561 effect on the outcome of development of TBEV and JEV nAbs as assessed at the end of the
562 study. Similar patterns were observed in plasmablast expansion, a B cell subset responsible for

563 secreting large amounts of antibodies following infection or vaccination [52]. Plasmablasts
564 expanded robustly in cohorts receiving the YFV vaccine (cohorts A1, A2, B1, B2 and E), a
565 finding consistent with previous studies of YFV vaccinated individuals [42,43,51,53–58].
566 Plasmablast expansion was not observed in the TBEV or JEV only cohorts (cohorts C and D)
567 upon primary vaccination. However, subsequent doses of TBEV or JEV vaccines led to detection
568 of some plasmablast expansion. As plasmablasts can derive from previously generated memory
569 B cells [59,60], more expansions may be expected after several doses of TBEV or JEV vaccine.
570 In summary, few differences in immunological responses were observed between concomitant
571 flavivirus vaccination and single vaccination, much of the responses observed likely due to the
572 YFV vaccine.

573 Co-administration of vaccines into the same or different upper arms allowed for
574 comparative studies between these different strategies of administering two different vaccines.
575 One advantage with administering vaccines in the same upper arm (or at the same site in
576 general) is that the other upper arm is not affected in terms of local reactogenicity responses.
577 That may save the dominant arm from possible functional impairment over the first days
578 following vaccination. As mentioned, no statistically significant differences between the study
579 and control cohorts' TNF or IL-18 serum comparing cohorts A1 with A2 or B1 with B2 were
580 observed. Similarly, no statistical differences were found in terms of the development of virus-
581 specific nAbs between the A1 and A2 or B1 and B2 cohorts as well as other B cell-related
582 responses including activation and plasmablasts expansion. The only observed statistically
583 significant difference noted between the same arm (A2 and B2) and different arm (A1 and B1)
584 concomitant vaccine cohorts was the frequency of activated CD4⁺ T cells being higher in cohort
585 B2 versus cohort B1. This said, TNF and IL-18, general lymphocyte activation, nAb titers, as

586 well as percentages of plasmablasts, were if anything slightly higher in the study groups where
587 concomitant vaccination had occurred in the same upper arm (A2 and B2) versus different upper
588 arms (A1 and B1). We cannot exclude the possibilities that adjuvant-like effects imposed by,
589 e.g., the live attenuated YFV vaccine or priming of immune cells in the same lymph node might
590 contribute to the effects observed.

591 The relative strength of the present study is that data were collected from a *bona fide*
592 prospective clinical trial with the scientific and regulatory rigor inherent to this design,
593 independent study monitoring of data, both of which contributed to data quality, and additionally
594 low drop-out rates and minimal risk of selection bias. An additional advantage was the ability to
595 include and compare two different inactivated whole virus vaccines, the TBEV and JEV
596 vaccines, respectively. The study contributes carefully evaluated clinical safety data in addition
597 to standard clinical virology, clinical chemistry, and clinical immunology data. The number and
598 frequency of study participant visits added to the strength of the study. With respect to
599 limitations of this study, even later sampling time-points would have allowed assessment of
600 sustainability of the developed nAbs and larger study groups could have given even more robust
601 data. Another relative limitation of the study is the fact that it did not include screening for
602 TBEV, JEV or YFV seropositivity prior to enrollment into the study. However, only two study
603 participants with positive nAbs against TBEV and no one to JEV or YFV were identified.

604 Concomitant vaccine administration strategies have been used in many child vaccination
605 programs [61,62] as well with travelers on their way to endemic regions [25,63]. Administration
606 of multiple vaccines at the same time is convenient as it reduces the number of clinical visits,
607 thus saving time and resources, and provides protection against multiple pathogens in a shorter
608 time-span when an individual may be vulnerable to infection. In addition, most reports deem

609 concomitant vaccinations safe and effective [25,29,64,65]. In this respect, the guidelines of the
610 US Food and Drug Administration (FDA) regarding the YFV vaccine YF-Vax (Sanofi Pasteur)
611 state that it can be administered with the that measles vaccine, diphtheria and tetanus toxoid and
612 whole cell pertussis vaccine (DTP), Hepatitis A and B vaccines, meningococcal vaccine, and
613 typhoid vaccine (www.fda.gov). Most regulatory authorities including the Swedish Medical
614 Products Agency recommend concomitant delivery of many vaccines, including the YFV
615 vaccine, at separate injection sites (www.lakemedelsverket.se/en). With respect to flavivirus
616 vaccines, the FDA specifically notes that the potential interference between the YFV vaccine and
617 JEV vaccines have not been established. In context of the COVID-19 pandemic, new vaccine
618 technologies have been successfully implemented and are now being tested when administered
619 concomitantly with seasonal influenza vaccines. The safety and immunogenicity data generated
620 from this clinical trial can provide insights into concomitant vaccination strategies using different
621 types of vaccine formulations that could aid in guiding new vaccination strategies of emerging
622 and re-emerging viral infections.

623 In conclusion, this clinical trial showed that concomitant TBEV or JEV vaccination with
624 the live attenuated YFV vaccine can be administered with little risk of severe adverse events and,
625 additionally, no impairment on the development of nAbs to the respective viruses. Finally, the
626 vaccines can readily be administered in the same upper arm.

627 **Acknowledgments**

628 We thank all study participants for participating in the clinical trial, the Karolinska Trial Alliance
629 staff and research nurses for organizing the recruitment and scheduling of study participants,
630 vaccination, and clinical sampling. Additionally, we thank J. Verner-Carlsson and staff scientists
631 at the Swedish Public Health Agency for support with neutralization assays and BSL-3
632 instruction. Further thanks to W. Christ for support in the BSL-3 facility, P. Jahnmatz for
633 discussions around the FluoroSpot reader assessment, and D. Wullimann for discussions and
634 advice on the project.

635

636 **Author Contributions**

637 Conceptualization: KB and H-GL; data curation: JTS, ML, KB; formal analysis: JTS, ML, KB;
638 funding acquisition: KB, H-GL; investigation: JTS, ML, RV, JE, KB; development of
639 methodology: JTS, ML, KB, KL; management and coordination responsibility: JTS, ML, KB, H-
640 GL; provision of study materials and samples: NA-T, LL, KB, H-GL; oversight and leadership:
641 JK, KL, KB, H-GL; verification: JTS, ML, NA-T, JK, KB; data visualization: JTS, ML, KB, H-
642 GL; writing initial draft: JTS, ML, KB, H-GL; manuscript review and revision: JTS, ML, RV,
643 JE, NA-T, LL, SG-R, JK, KL, KB, H-GL.

644

645

646

647

648

649 **References**

- 650 1. Daep CA, Muñoz-Jordán JL, Eugenin EA. Flaviviruses, an expanding threat in public health:
651 focus on dengue, West Nile, and Japanese encephalitis virus. *J Neurovirol.* 2014;20: 539–560.
652 doi:10.1007/s13365-014-0285-z
- 653 2. Gershman MD, Staples JE. Netter’s Infectious Diseases. Sect Vii Infect Assoc Int Travel
654 Outdoor Activities. 2012; 383–389. doi:10.1016/b978-1-4377-0126-5.00064-1
- 655 3. Dumpis U, Crook D, Oksi J. Tick-Borne Encephalitis. *Clin Infect Dis.* 1999;28: 882–890.
656 doi:10.1086/515195
- 657 4. Haglund M, Gunther G. Tick-borne encephalitis—pathogenesis, clinical course and long-term
658 follow-up. *Vaccine.* 2003;21: S11--S18. doi:10.1016/s0264-410x(02)00811-3
- 659 5. Yellow fever. 7 May 2019 [cited 2 Feb 2022]. Available: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/yellow-fever)
660 [room/fact-sheets/detail/yellow-fever](https://www.who.int/news-room/fact-sheets/detail/yellow-fever)
- 661 6. Bogovič P, Lotrič-Furlan S, Avšič-Županc T, Korva M, Kastrin A, Lusa L, et al. Comparison
662 of Clinical, Laboratory and Immune Characteristics of the Monophasic and Biphasic Course of
663 Tick-Borne Encephalitis. *Microorg.* 2021;9: 796. doi:10.3390/microorganisms9040796
- 664 7. Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese
665 encephalitis virus infection in the adult and pediatric age group with Acute Encephalitis
666 Syndrome. *J Clin Virol.* 2011;52: 45–49. doi:10.1016/j.jcv.2011.06.001
- 667 8. Tick-borne encephalitis. 2 Oct 2017 [cited 2 Feb 2022]. Available:
668 https://www.who.int/health-topics/tick-borne-encephalitis#tab=tab_1
- 669 9. Japanese encephalitis. 9 May 2019 [cited 2 Feb 2022]. Available:
670 <https://www.who.int/en/news-room/fact-sheets/detail/japanese-encephalitis>
- 671 10. Riccardi N, Antonello RM, Luzzati R, Zajkowska J, Bella SD, Giacobbe DR. Tick-borne
672 encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. *Eur*
673 *J Intern Med.* 2019;62: 1–6. doi:10.1016/j.ejim.2019.01.004
- 674 11. Son H, Sunwoo J-S, Lee SK, Chu K, Lee S-T. Clinical Outcomes of Japanese Encephalitis
675 after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon- α 2b. *J Clin Neurol.*
676 2021;17: 428–434. doi:10.3988/jcn.2021.17.3.428
- 677 12. Douam F, Ploss A. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old
678 Foe. *Trends Microbiol.* 2018;26: 913–928. doi:10.1016/j.tim.2018.05.012

- 679 13. Tokunaga M, Miyamoto Y, Suzuki T, Otani M, Inuki S, Esaki T, et al. Novel anti-flavivirus
680 drugs targeting the nucleolar distribution of core protein. *Virology*. 2020;541: 41–51.
681 doi:10.1016/j.virol.2019.11.015
- 682 14. Felicetti T, Manfroni G, Cecchetti V, Cannalire R. Broad-Spectrum Flavivirus Inhibitors: a
683 Medicinal Chemistry Point of View. *Chemmedchem*. 2020;15: 2391–2419.
684 doi:10.1002/cmde.202000464
- 685 15. FSME-IMMUN Vuxen - FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
686 [https://www.fass.se/LIF/product?userType=0&nplId=20040206000026&docType=7&scrollPosit](https://www.fass.se/LIF/product?userType=0&nplId=20040206000026&docType=7&scrollPosition=255)
687 [ion=255](https://www.fass.se/LIF/product?userType=0&nplId=20040206000026&docType=7&scrollPosition=255)
- 688 16. IXIARO® - FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
689 <https://www.fass.se/LIF/product?userType=0&nplId=20080207000014>
- 690 17. Stamaril® - FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
691 <https://www.fass.se/LIF/product?userType=0&nplId=19940408000036>
- 692 18. Gotuzzo E, Yactayo S, Cordova E. Review article: Efficacy and duration of immunity after
693 yellow fever vaccination: Systematic review on the need for a booster every 10 years. *Am J*
694 *Tropical Medicine Hyg*. 2013;89: 434--444. doi:10.4269/ajtmh.13-0264
- 695 19. Plotkin SA. Correlates of Protection Induced by Vaccination ∇ . *Clin Vaccine Immunol*.
696 2010;17: 1055–1065. doi:10.1128/cvi.00131-10
- 697 20. Plotkin SA, Orenstein WA, Offit P, Edwards KM. Plotkin’s Vaccines. 7th Editio.
698 Philadelphia, PA: Elsevier; 2017.
- 699 21. Lindquist L, Vapalahti O. Tick-borne encephalitis. *Lancet*. 2008;371: 1861--1871.
700 doi:10.1016/s0140-6736(08)60800-4
- 701 22. Björk A, Morelli V. Immunization Strategies for Healthcare Practices and Providers | CDC.
702 In: *Immunization Strategies for Healthcare Practices and Providers* [Internet]. 2021 [cited 20 Feb
703 2022]. Available: <https://www.cdc.gov/vaccines/pubs/pinkbook/strat.html>
- 704 23. Ambrosch F, Fritzell B, Gregor J, Jonas S, Kollaritsch H, Teulieres L, et al. Combined
705 vaccination against yellow fever and typhoid fever: a comparative trial. *Vaccine*. 1994;12: 625–
706 628. doi:10.1016/0264-410x(94)90267-4
- 707 24. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, et al. Concomitant or
708 sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and
709 yellow fever 17D vaccine. *Hum Vaccines*. 2010;6: 906–914. doi:10.4161/hv.6.11.12854
- 710 25. Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, et al. Evaluation
711 of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine

- 712 administered concomitantly with a Japanese encephalitis vaccine. *Travel Med Infect Di.*
713 2015;13: 241–250. doi:10.1016/j.tmaid.2015.05.008
- 714 26. López P, Lanata CF, Zambrano B, Cortés M, Andrade T, Amemiya I, et al. Immunogenicity
715 and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a
716 Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in
717 Colombia and Peru. *Pediatric Infect Dis J.* 2016;35: 1140–1147.
718 doi:10.1097/inf.0000000000001250
- 719 27. Silva JRN, Camacho LAB, Siqueira MM, Freire M de S, Castro YP, Maia M de LS, et al.
720 Mutual interference on the immune response to yellow fever vaccine and a combined vaccine
721 against measles, mumps and rubella. *Vaccine.* 2011;29: 6327–6334.
722 doi:10.1016/j.vaccine.2011.05.019
- 723 28. Kreil TR, Burger I, Attakpah E, Olas K, Eibl MM. Passive immunization reduces immunity
724 that results from simultaneous active immunization against tick-borne encephalitis virus in a
725 mouse model. *Vaccine.* 1998;16: 955–959. doi:10.1016/s0264-410x(97)00304-6
- 726 29. Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, et al. Safety
727 and immunogenicity of concomitant vaccination with the cell-culture based Japanese
728 Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A
729 single-blind, randomized, controlled Phase 3 study. *Vaccine.* 2009;27: 4483–4489.
730 doi:10.1016/j.vaccine.2009.05.034
- 731 30. Konishi E, Terazawa A, Imoto J. Simultaneous immunization with DNA and protein
732 vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to
733 induce neutralizing antibody in mice. *Vaccine.* 2003;21: 1826–1832. doi:10.1016/s0264-
734 410x(03)00028-8
- 735 31. Fletcher MA, Fabre P, Debois H, Saliou P. Vaccines administered simultaneously: directions
736 for new combination vaccines based on an historical review of the literature. *Int J Infect Dis.*
737 2004;8: 328–338. doi:10.1016/j.ijid.2004.03.006
- 738 32. Pilewski KA, Kramer KJ, Georgiev IS. Simultaneous Immunization with Multiple Diverse
739 Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity. *Nato Adv*
740 *Sci Inst Se.* 2021;9: 964. doi:10.3390/vaccines9090964
- 741 33. Coursaget P, Fritzell B, Blondeau C, Saliou P, Diop-Mar I. Simultaneous injection of
742 plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines.
743 *Vaccine.* 1995;13: 109–111. doi:10.1016/0264-410x(95)80020-e
- 744 34. Tauraso NM, Myers MG, Nau EV, O'Brien TC, Spindel SS, Trimmer RW. Effect of interval
745 between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man. *J Infect*
746 *Dis.* 1972;126: 362–71. doi:10.1093/infdis/126.4.362

- 747 35. Felsenfeld O, Wolf RobertH, Gyr K, Grant LouisS, Dutta NirmalK, Zarifi AZ, et al.
748 SIMULTANEOUS VACCINATION AGAINST CHOLERA AND YELLOW FEVER. *Lancet*.
749 1973;301: 457–458. doi:10.1016/s0140-6736(73)91882-5
- 750 36. Kaaijk P, Luytjes W. Are we prepared for emerging flaviviruses in Europe? Challenges for
751 vaccination. *Hum Vacc Immunother*. 2017;14: 337–344. doi:10.1080/21645515.2017.1389363
- 752 37. Lukan M, Bullova E, Petko B. Climate Warming and Tick-borne Encephalitis, Slovakia -
753 Volume 16, Number 3—March 2010 - *Emerging Infectious Diseases journal - CDC*. *Emerg*
754 *Infect Dis*. 2010;16: 524–526. doi:10.3201/eid1603.081364
- 755 38. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. *Nat Microbiol*.
756 2020;5: 796–812. doi:10.1038/s41564-020-0714-0
- 757 39. ICH GCP - ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for
758 Good Clinical Practice ICH E6(R2) ICH Consensus Guideline - ICH GCP. [cited 31 Jan 2022].
759 Available: <https://ichgcp.net/sv>
- 760 40. Miller JD, Most RG van der, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human
761 Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines.
762 *Immunity*. 2008;28: 710--722. doi:10.1016/j.immuni.2008.02.020
- 763 41. Vene S, Haglund M, Vapalahti O, Lundkvist A. A rapid fluorescent focus inhibition test for
764 detection of neutralizing antibodies to tick-borne encephalitis virus. *J Virol Methods*. 1998;73:
765 71--75. doi:10.1016/s0166-0934(98)00041-x
- 766 42. Marquardt N, Ivarsson MA, Blom K, Gonzalez VD, Braun M, Falconer K, et al. The Human
767 NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation
768 Independently of NK Cell Education. *J Immunol*. 2015;195: 3262--3272.
769 doi:10.4049/jimmunol.1401811
- 770 43. Sandberg JT, Ols S, Löfling M, Varnaitè R, Lindgren G, Nilsson O, et al. Activation and
771 Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and
772 Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination. *J Immunol*.
773 2021;207: ji2001381. doi:10.4049/jimmunol.2001381
- 774 44. Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al. Safety
775 and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN®:
776 Results of two large phase 3 clinical studies. *Vaccine*. 2006;24: 5256–5263.
777 doi:10.1016/j.vaccine.2006.03.061
- 778 45. Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the
779 Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. *Vaccine*. 2011;29:
780 8669–8676. doi:10.1016/j.vaccine.2011.08.117

- 781 46. Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17-
782 year review. *Expert Rev Vaccines*. 2014;12: 1351–1368. doi:10.1586/14760584.2013.836320
- 783 47. Blom K, Sandberg JT, Loré K, Ljunggren H-G. Prospects for induction of CD8 T cell-
784 mediated immunity to Zika virus infection by yellow fever virus vaccination. *J Intern Med*.
785 2017;282: 206–208. doi:10.1111/joim.12638
- 786 48. Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of
787 the Japanese encephalitis serocomplex. *Expert Rev Vaccines*. 2014;11: 177–187.
788 doi:10.1586/erv.11.180
- 789 49. Saron WAA, Rathore APS, Ting L, Ooi EE, Low J, Abraham SN, et al. Flavivirus
790 serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T
791 cells. *Sci Adv*. 2018;4: eaar4297. doi:10.1126/sciadv.aar4297
- 792 50. Yamshchikov G, Borisevich V, Kwok CW, Nistler R, Kohlmeier J, Seregin A, et al. The
793 suitability of yellow fever and Japanese encephalitis vaccines for immunization against West
794 Nile virus. *Vaccine*. 2005;23: 4785–4792. doi:10.1016/j.vaccine.2005.04.036
- 795 51. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal
796 dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an
797 effector- to a memory-type response. *J Immunol*. 2013;190: 2150–8.
798 doi:10.4049/jimmunol.1202234
- 799 52. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting
800 plasma cells. *Nat Rev Immunol*. 2015;15: 160–171. doi:10.1038/nri3795
- 801 53. Wieten RW, Jonker EFF, Leeuwen EMMV, Remmerswaal EBM, Berge IJMT, Visser AWD,
802 et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of
803 yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. Shoukry NH,
804 editor. *Plos One*. 2016;11: e0149871. doi:10.1371/journal.pone.0149871
- 805 54. Azamor T, Silva AMV da, Melgaço JG, Santos AP dos, Xavier-Carvalho C, Alvarado-Arnez
806 LE, et al. Activation of an Effective Immune Response after Yellow Fever Vaccination Is
807 Associated with the Genetic Background and Early Response of IFN- γ and CLEC5A. *Viruses*.
808 2021;13: 96. doi:10.3390/v13010096
- 809 55. Martins MÂ, Silva ML, Marciano APV, Peruhype-Magalhães V, Eloi-Santos SM, Ribeiro
810 JGL, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD
811 yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following
812 immunization? *Clin Exp Immunol*. 2007;148: 90–100. doi:10.1111/j.1365-2249.2006.03317.x
- 813 56. Davydov AN, Obraztsova AS, Lebedin MY, Turchaninova MA, Staroverov DB, Merzlyak
814 EM, et al. Comparative Analysis of B-Cell Receptor Repertoires Induced by Live Yellow Fever
815 Vaccine in Young and Middle-Age Donors. *Front Immunol*. 2018;9: 2309.
816 doi:10.3389/fimmu.2018.02309

- 817 57. Costa-Rocha IA da, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-dos-Reis JG,
818 Fradico JRB, Souza-Lopes T, et al. Duration of Humoral and Cellular Immunity 8 Years After
819 Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine. *Front Immunol.* 2019;10:
820 1211. doi:10.3389/fimmu.2019.01211
- 821 58. Huber JE, Ahlfeld J, Scheck MK, Zaucha M, Witter K, Lehmann L, et al. Dynamic changes
822 in circulating T follicular helper cell composition predict neutralising antibody responses after
823 yellow fever vaccination. *Clin Transl Immunol.* 2020;9: 1--16. doi:10.1002/cti2.1129
- 824 59. Priyamvada L, Cho A, Onlamoon N, Zheng N-Y, Huang M, Kovalenkov Y, et al. B Cell
825 Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive,
826 Memory-Derived Plasmablasts. *J Virol.* 2016;90: 5574–5585. doi:10.1128/jvi.03203-15
- 827 60. Sundling C, Lau AWY, Bourne K, Young C, Laurianto C, Hermes JR, et al. Positive
828 selection of IgG⁺ over IgM⁺ B cells in the germinal center reaction. *Immunity.* 2021;54: 1--14.
829 doi:10.1016/j.immuni.2021.03.013
- 830 61. Zhao Z, Smith PJ, Hill HA. Evaluation of potentially achievable vaccination coverage with
831 simultaneous administration of vaccines among children in the United States. *Vaccine.* 2016;34:
832 3030–3036. doi:10.1016/j.vaccine.2016.04.097
- 833 62. HESLEY TM, REISINGER KS, SULLIVAN BJ, JENSEN EH, STASIOROWSKI S,
834 MEECHAN CD, et al. Concomitant administration of a bivalent Haemophilus influenzae type b-
835 hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine; safety,
836 tolerability and immunogenicity. *Pediatric Infect Dis J.* 2004;23: 240–245.
837 doi:10.1097/01.inf.0000114902.84651.02
- 838 63. Hoecke C, Lebacqz E, Beran J, Prymula R, Collard F. Concomitant Vaccination against
839 Hepatitis A and Typhoid Fever. *J Travel Med.* 1998;5: 116–120. doi:10.1111/j.1708-
840 8305.1998.tb00483.x
- 841 64. Wang SV, Abdurrob A, Spoenlin J, Lewis E, Newcomer SR, Fireman B, et al. Methods for
842 addressing “innocent bystanders” when evaluating safety of concomitant vaccines.
843 *Pharmacoepidemiol Drug Saf.* 2018;27: 405–412. doi:10.1002/pds.4399
- 844 65. Falsey AR, Walsh EE, Scott DA, Gurtman A, Zareba A, Jansen KU, et al. Phase 1/2
845 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F
846 Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. *J Infect Dis.* 2021; jia611-
847 doi:10.1093/infdis/jia611
- 848
- 849

850 **Supporting information**

851 **S1 Fig. Soluble cytokine concentrations in serum following vaccination.** (A) Heat map of
852 fold changes of all detectable soluble factors in serum following vaccination. (B) Box and
853 whisker plots comparing serum TNF and IL-18 concentrations following the first vaccine dose.
854 The legend denotes color-coding of the seven cohorts. Statistical analyses were performed using
855 nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple comparison tests.

856 **S2 Fig. Sex-based comparisons of final virus nAb titers.** (A) Comparisons of male (M) vs female (F)
857 TBEV nAb titers at the final time point in cohort A1 and A2 (left panel), cohort C (middle panel) and
858 combined A and C cohorts (right panel). (B) Comparisons of male (M) vs female (F) JEV nAb titers at
859 the final time point in cohort B1 and B2 (left panel), cohort D (middle panel) and combined B and D
860 cohorts (right panel). (C) Comparisons of male (M) vs female (F) YFV nAb titers at the final time point
861 in cohort E (left panel) and combined A, B, and E cohorts (right panel). The legend denotes color-coding
862 of the seven cohorts. Statistical analyses were performed using nonparametric Friedman and Kruskal-
863 Wallis test with Dunn's multiple comparison tests. * $p < 0.05$.

864 **S3 Fig. Immunoglobulin expression of circulating plasmablasts.** (A) Median IgG expression
865 of plasmablasts over time following vaccination and comparison of peak expression between
866 cohorts at days (B) 14, (C) 37 and (D) 187. (E) Median IgA expression of plasmablasts over time
867 following vaccination and (F) comparison of lowest expression between cohorts at day14. (G)
868 Median IgG-A- expression of plasmablasts over time following vaccination and (H) comparison
869 of peak expression between cohorts at day14. The legend denotes color-coding of the seven
870 cohorts. All plots are depicted with median values with IQR. Statistical analyses were performed

871 using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. * $p < 0.05$, ** p
872 < 0.01 , *** $p < 0.001$.

873 **S1 Table.** List of adverse events following vaccination

874 **S2 Table.** Summary of registered adverse events

875 **FIGURE LEGENDS**

876 **Fig. 1 | Clinical trial layout for study participants and vaccination strategy with sampling**

877 **timeline.** (A) The flowchart depicts the screening and enrollment of healthy volunteers in the
878 study. Enrolled study participants were divided into seven vaccine cohorts. Study participant
879 dropouts and total missed visits are depicted. (B) Schematic of vaccination strategy and sampling
880 schedule for enrolled study participants. Peripheral blood and serum samples were taken at the
881 time-points indicated by blood drop symbol. See Material and Methods for vaccination details.

882

883 **Fig. 2 | Clinical laboratory assessment following concomitant flavivirus vaccination. (A)**

884 Total number of YFV RNA copies/mL serum in cohorts receiving YFV vaccine. (B) Comparison
885 of day 7 YFV RNA copies/mL between cohorts (plot depicts median with IQR). (C) Median
886 clinical chemistry data-points during first four time-points of the study. Grey backgrounds
887 denote the normal range in healthy adults. (D) Total numbers of CD45⁺, CD4⁺, and CD8⁺ cells
888 over time following vaccination (left panels) and comparison of day 14 median absolute cell
889 numbers in the respective vaccine cohorts (right panels, plots depict median with IQR). (E) Heat-
890 map of fold change of serum TNF and IL-18 levels following the first vaccine dose. The legend
891 denotes color-coding of the seven cohorts. Statistical analyses in (A), (C), and (E) were
892 performed using nonparametric Friedman test with Dunn's multiple comparison tests, in (B) and
893 (D day 14 plots), using nonparametric Kruskal-Wallis test with Dunn's multiple comparison
894 tests, and in (D timeline) using nonparametric Wilcoxon matched-pairs signed-rank tests. *p <
895 0.05, **p < 0.01, ***p < 0.001.

896

897 **Fig. 3 | Seroconversion and development of neutralizing antibody following concomitant**
898 **flavivirus vaccination. (A)** TBEV specific IgG levels before and after concomitant vaccination
899 with TBEV and YFV or only TBEV. The dotted line denotes manufacturer's positive threshold
900 and samples ≥ 1000 Vienna units were plotted at 1000 Vienna units. **(B)** Comparisons of final
901 TBEV-specific IgG levels between cohorts A1, A2 and C. **(C)** JEV specific IgG levels before
902 and after concomitant vaccination with JEV and YFV or only JEV. The dotted line denotes
903 manufacturer's positive threshold and samples ≥ 200 RU/mL were plotted at 200 RU/mL. **(D)**
904 Comparisons of final JEV-specific IgG levels between cohorts B1, B2 and D. **(E)** TBEV
905 neutralizing antibody titers before and at days 30 and 210 after concomitant vaccination with
906 TBEV and YFV or only TBEV. Study participants with nAbs detected at day 0 (A1, n = 1; A2, n
907 = 1) excluded from figures. The dotted line denotes positive threshold (≥ 5). **(F)** Comparisons of
908 final nAb titers against TBEV between cohorts (percent seropositive individuals as denoted
909 above). **(G)** JEV neutralizing antibody titers before and at days 30 and 60 after concomitant
910 vaccination against JEV and YFV or only JEV. Dotted line denotes positive threshold (≥ 5). **(H)**
911 Comparisons of final nAbs titers against JEV between cohorts (percent seropositive individuals
912 as denoted above). **(I)** YFV neutralizing antibody titers before and at days 30 and 60 after
913 concomitant vaccination with TBEV or JEV and YFV, or only YFV. The dotted line denotes
914 positive threshold (≥ 5). **(J)** Comparisons of final nAbs titers against YFV between respective
915 cohorts. The legend denotes color coding of the seven cohorts. All plots are depicted with
916 median values. Statistical analyses in **(A)**, **(C)**, **(E)**, **(G)**, and **(I)** were performed using
917 nonparametric Friedman test with Dunn's multiple comparison tests and in **(B)**, **(D)**, **(F)**, **(H)**,
918 and **(J)** using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. *p <
919 0.05, **p < 0.01, ***p < 0.001.

920

921 **Fig. 4 | B cell, T cell and NK cell activation following concomitant flavivirus vaccination.**

922 (A) Representative gating strategy identifying B cells, CD4⁺ and CD8⁺ T cells as well as
923 CD56^{dim} NK cells. Representative FACS plot of CD38⁺ Ki67⁺ (B) B cells, (C) CD4⁺ T cells, (D)
924 CD8⁺ T cells, and (E) CD56^{dim} NK cells (left panels) with corresponding plot of the respective
925 cohorts' frequency of activation medians before and following vaccination program (middle
926 panels). Plots comparing peak activation at day 14 between the vaccination cohorts (right panels
927 depicting median values with IQR). The legend denotes color-coding of the seven cohorts.
928 Statistical analyses were performed using nonparametric Kruskal-Wallis test with Dunn's
929 multiple comparison tests. *p < 0.05 and ***p < 0.001.


930

931 **Fig. 5 | Germinal center activity and plasmablast expansion following concomitant**

932 **flavivirus vaccination.** (A) Median CXCL13 serum fold changes over time following
933 vaccination program (left panel), and comparison of peak levels between cohorts at days 7 and
934 14 (right panel). (B) Representative gating strategy for identifying plasmablasts. (C) Median
935 plasmablast expansion over time following vaccination and (D) comparison of peak expansion
936 between cohorts at day 14. The legend denotes color-coding of the seven cohorts. All plots are
937 depicted with median values with IQR. Statistical analyses were performed using nonparametric
938 Kruskal-Wallis test with Dunn's multiple comparison tests. *p < 0.05, **p < 0.01, ***p < 0.001.

Figure 1

A



medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B





Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3




Figure 4





Figure 5

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



S Table 1 Adverse events after vaccination

Cohort A1
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Respiratory, thoracic and mediastinal disorders
Metabolism and nutrition disorders
Infections and infestations
Injury, poisoning and procedural complications
Ear and labyrinth disorders
Reproductive system and breast disorders
Total

Cohort A2
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Respiratory, thoracic and mediastinal disorders
Infections and infestations
Injury, poisoning and procedural complications
Skin and subcutaneous tissue disorders
Blood and lymphatic system disorders
Reproductive system and breast disorders
Total

Cohort B1
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Reproductive system and breast disorders
Respiratory, thoracic and mediastinal disorders
Infections and infestations
Psychiatric disorders
Others (no SOC)
Total

Cohort B2
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Infections and infestations
Blood and lymphatic system disorders
Total

Cohort C
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Metabolism and nutrition disorders
Infections and infestations
Respiratory, thoracic and mediastinal disorders
Injury, poisoning and procedural complications
Reproductive system and breast disorders
Psychiatric disorders
Total

Cohort D
System organ class & AE
General disorders and administrative site conditions
Nervous system disorders
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Infections and infestations
Respiratory, thoracic and mediastinal disorders
Total


Cohort E
System organ class & AE
General disorders and administrative site conditions
Musculoskeletal and connective tissue disorders
Gastro-intestinal disorders
Infections and infestations
Respiratory, thoracic and mediastinal disorders
Total

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.


Supplementary Table 2 | Summary of registered adverse events

	A1 (n=23)	A2 (n=20)	B1 (n=21)	B2 (n=21)	C (n=20)	D (n=20)	E (n=20)	Totalt (n=145)
Total AE	42	52	26	21	37	31	19	228
Donors with at least one AE	19	16	12	10	16	16	11	100
Severity:								
Mild	37	36	22	14	27	25	16	177
Moderate	4	15	4	7	9	6	2	47
Severe	1	1	0	0	1	0	1	4
Related to vaccination								
Unlikely	25	37	19	10	21	20	16	148
Possible	8	3	2	8	6	1	2	30
Probable	9	12	5	3	10	10	1	50
Related total	17	15	7	11	16	11	3	80

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




S1 Fig. Soluble cytokine concentrations in serum following vaccination. (A) Heat map of fold changes of all detectable soluble factors in serum following vaccination. (B) Box and whisker plots comparing serum TNF and IL-18 concentrations following the first vaccine dose. The legend denotes color-coding of the seven cohorts. Statistical analyses were performed using nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple comparison tests.

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



S2 Fig. Sex-based comparisons of final virus nAb titers. (A) Comparisons of male (M) vs female (F) TBEV nAb titers at the final time point in cohort A1 and A2 (left panel), cohort C (middle panel) and combined A and C cohorts (right panel). (B) Comparisons of male (M) vs female (F) JEV nAb titers at the final time point in cohort B1 and B2 (left panel), cohort D (middle panel) and combined B and D cohorts (right panel). (C) Comparisons of male (M) vs female (F) YFV nAb titers at the final time point in cohort E (left panel) and combined A, B, and E cohorts (right panel). The legend denotes color-coding of the seven cohorts. Statistical analyses were performed using nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple comparison tests. * $p < 0.05$.



medRxiv preprint doi: <https://doi.org/10.1101/2022.07.05.22277040>; this version posted July 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

S3 Fig. Immunoglobulin expression of circulating plasmablasts. (A) Median IgG expression of plasmablasts over time following vaccination and comparison of peak expression between cohorts at days (B) 14, (C) 37 and (D) 187. (E) Median IgA expression of plasmablasts over time following vaccination and (F) comparison of lowest expression between cohorts at day 14. (G) Median IgG-A- expression of plasmablasts over time following vaccination and (H) comparison of peak expression between cohorts at day 14. The legend denotes color-coding of the seven cohorts. All plots are depicted with median values with IQR. Statistical analyses were performed using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.